Immunological data from cancer patients treated with Ad5/3-E2F-Delta 24-GMCSF suggests utility for tumor immunotherapy

Otto Hemminki; Suvi Parviainen; Juuso Juhila; Riku Turkki; Nina Linder; Johan Lundin; Matti Kankainen; Ari Ristimaki; Anniina Koski; Ilkka Liikanen; Minna Oksanen; Dirk M. Nettelbeck; Kalevi Kairemo; Kaarina Partanen; Timo Joensuu; Anna Kanerva; Akseli Hemminki

doi:10.18632/oncotarget.2901

Immunological data from cancer patients treated with Ad5/3-E2F-Delta 24-GMCSF suggests utility for tumor immunotherapy

Otto Hemminki, Suvi Parviainen, Juuso Juhila, Riku Turkki, Nina Linder, Johan Lundin, Matti Kankainen, Ari Ristimaki, Anniina Koski, Ilkka Liikanen, Minna Oksanen, Dirk M. Nettelbeck, Kalevi Kairemo, Kaarina Partanen, Timo Joensuu, Anna Kanerva, Akseli Hemminki

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

Originalspråk	engelska
Tidskrift	Oncotarget
Volym	6
Nummer	6
Sidor (från-till)	4467-4481
Antal sidor	15
ISSN	1949-2553
DOI	https://doi.org/10.18632/oncotarget.2901
Status	Publicerad - 28 feb. 2015
MoE-publikationstyp	A1 Tidskriftsartikel-refererad

Vetenskapsgrenar

3122 Cancersjukdomar

Åtkomst av dokument

10.18632/oncotarget.2901Licens: CC BY

2901-41148-3-PBSlutlig publicerad version, 2,81 MBLicens: CC BY

Citera det här

Hemminki, O., Parviainen, S., Juhila, J., Turkki, R., Linder, N., Lundin, J., Kankainen, M., Ristimaki, A., Koski, A., Liikanen, I., Oksanen, M., Nettelbeck, D. M., Kairemo, K., Partanen, K., Joensuu, T., Kanerva, A., & Hemminki, A. (2015). Immunological data from cancer patients treated with Ad5/3-E2F-Delta 24-GMCSF suggests utility for tumor immunotherapy. Oncotarget, 6(6), 4467-4481. https://doi.org/10.18632/oncotarget.2901

@article{36ad51952efa410c8a30fd0fb3fc9c71,

title = "Immunological data from cancer patients treated with Ad5/3-E2F-Delta 24-GMCSF suggests utility for tumor immunotherapy",

keywords = "Oncolytic, immunotherapy, cancer, ATAP, CHEMOTHERAPY-REFRACTORY CANCER, ANTITUMOR IMMUNE-RESPONSES, COLONY-STIMULATING FACTOR, ONCOLYTIC ADENOVIRUS, OVARIAN-CANCER, T-CELL, GM-CSF, THERAPEUTIC-EFFICACY, RETINOIC ACID, SOLID TUMORS, 3122 Cancers",

author = "Otto Hemminki and Suvi Parviainen and Juuso Juhila and Riku Turkki and Nina Linder and Johan Lundin and Matti Kankainen and Ari Ristimaki and Anniina Koski and Ilkka Liikanen and Minna Oksanen and Nettelbeck, {Dirk M.} and Kalevi Kairemo and Kaarina Partanen and Timo Joensuu and Anna Kanerva and Akseli Hemminki",

year = "2015",

month = feb,

day = "28",

doi = "10.18632/oncotarget.2901",

language = "English",

volume = "6",

pages = "4467--4481",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "6",

}

Hemminki, O, Parviainen, S, Juhila, J, Turkki, R , Linder, N , Lundin, J , Kankainen, M , Ristimaki, A , Koski, A, Liikanen, I, Oksanen, M, Nettelbeck, DM, Kairemo, K, Partanen, K, Joensuu, T, Kanerva, A & Hemminki, A 2015, 'Immunological data from cancer patients treated with Ad5/3-E2F-Delta 24-GMCSF suggests utility for tumor immunotherapy', Oncotarget, vol. 6, nr. 6, s. 4467-4481. https://doi.org/10.18632/oncotarget.2901

TY - JOUR

T1 - Immunological data from cancer patients treated with Ad5/3-E2F-Delta 24-GMCSF suggests utility for tumor immunotherapy

AU - Hemminki, Otto

AU - Parviainen, Suvi

AU - Juhila, Juuso

AU - Turkki, Riku

AU - Linder, Nina

AU - Lundin, Johan

AU - Kankainen, Matti

AU - Ristimaki, Ari

AU - Koski, Anniina

AU - Liikanen, Ilkka

AU - Oksanen, Minna

AU - Nettelbeck, Dirk M.

AU - Kairemo, Kalevi

AU - Partanen, Kaarina

AU - Joensuu, Timo

AU - Kanerva, Anna

AU - Hemminki, Akseli

PY - 2015/2/28

Y1 - 2015/2/28

KW - Oncolytic

KW - immunotherapy

KW - cancer

KW - ATAP

KW - CHEMOTHERAPY-REFRACTORY CANCER

KW - ANTITUMOR IMMUNE-RESPONSES

KW - COLONY-STIMULATING FACTOR

KW - ONCOLYTIC ADENOVIRUS

KW - OVARIAN-CANCER

KW - T-CELL

KW - GM-CSF

KW - THERAPEUTIC-EFFICACY

KW - RETINOIC ACID

KW - SOLID TUMORS

KW - 3122 Cancers

U2 - 10.18632/oncotarget.2901

DO - 10.18632/oncotarget.2901

M3 - Article

SN - 1949-2553

VL - 6

SP - 4467

EP - 4481

JO - Oncotarget

JF - Oncotarget

IS - 6

ER -